Zai Lab Ltd (9688) AI Stock Analysis

• Market Cap: HK$16.36B
• Dividend Yield: N/A
• Average Volume (3M): 10.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: 23.87%
• EPS Growth: 30.08%
• Country: HK
• Employees: 1,869
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 1,128,128,000
• 10 Day Avg. Volume: 10,854,931
• 30 Day Avg. Volume: 10,116,373
• PEG Ratio: 0.28
• Price to Book (P/B): 2.68
• Price to Sales (P/S): 4.17
• P/FCF Ratio: -12.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$24.92
• Price Target Upside: 70.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -1.28
• Revenue Forecast (FY): HK$3.97B

• Rating: 47 Neutral
• Price Target: HK$15.00 ▲(2.74% Upside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is held back primarily by weak profitability and ongoing cash burn despite strong revenue scaling and healthy gross margins. Technicals add modest support due to improving short-term momentum, while valuation remains constrained by negative earnings and no dividend yield data.

Positive Factors

Revenue scale & growth

Sustained revenue scaling to $460.8M (2025) shows durable commercial traction and distribution reach. Larger revenue base supports investments in R&D and commercialization, improves operating leverage potential, and reduces reliance on single-product outcomes over the medium term.

Strong product-level margins

A ~58% gross margin indicates attractive product economics and pricing power versus peers. Sustainable high gross margins provide room to fund R&D and commercial expansion while cushioning the operating model as the company scales, supporting long-term profitability potential.

Integrated U.S./China R&D & commercial infrastructure

Having built integrated U.S./China capabilities is a structural competitive advantage: it accelerates global trials, enables parallel regulatory pathways, broadens market access, and can lower cycle times and costs for late-stage assets, improving probability of global commercialization.

Negative Factors

Persistent unprofitability

Large negative net and EBIT margins show the company still burns profits despite revenue scale. Ongoing operating losses erode shareholder value, limit reinvestment capacity from earnings, and mean long-term viability depends on sustained funding or rapid margin improvement.

Continued cash burn

Material negative operating and free cash flows indicate ongoing funding needs. Even with some improvement versus 2024, persistent cash burn raises refinance and dilution risk, constraining strategic optionality and making long-term execution dependent on external capital or milestone receipts.

Rising leverage & negative ROE

Increased leverage alongside a deeply negative ROE signals shareholder capital erosion and higher fixed obligations. This combination reduces financial flexibility, raises vulnerability to adverse market or clinical outcomes, and increases the cost of incremental funding over time.

Zai Lab Ltd Business Overview & Revenue Model

Company Description

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

How the Company Makes Money

Zai Lab generates revenue through several key streams. Primarily, the company earns money from the sale of its proprietary drugs once they receive regulatory approval and are commercially launched. Additionally, Zai Lab benefits from milestone payments and royalties from partnerships with larger pharmaceutical companies, which are often structured around co-development and co-commercialization agreements. These partnerships not only provide upfront capital and financial support but also enhance Zai Lab's market reach and product development capabilities. Clinical trial funding and government grants also contribute to its revenue, along with potential licensing agreements for its drugs in other markets. The strategic collaborations with established players in the industry play a crucial role in driving its earnings and expanding its portfolio.

Zai Lab Ltd Financial Statement Overview

Summary

Revenue has grown substantially over time and gross margin is strong (~58% in 2025), but the company remains meaningfully unprofitable (2025 net margin -38.1%, EBIT margin -49.9%). Cash flow is the biggest weakness, with continued operating and free cash burn in 2025 despite some improvement versus 2024, while leverage has risen and ROE remains strongly negative.

Income Statement

Revenue has scaled meaningfully over the period (from $49.0M in 2020 to $460.8M in 2025), with solid 2025 growth (+4.349). Gross margins remain strong for the sector (about 58% in 2025), indicating good product-level economics. However, profitability is still weak: 2025 net margin is -38.1% and operating losses remain sizable (EBIT margin -49.9%), even though losses have narrowed materially versus earlier years.

Balance Sheet

The company retains a sizable equity base ($715.4M in 2025) and a moderate leverage profile (debt-to-equity ~0.33 in 2025). That said, leverage has increased versus prior years, and returns on equity remain meaningfully negative (ROE about -24.6% in 2025), reflecting ongoing losses and pressure on shareholder capital despite revenue growth.

Cash Flow

Cash generation remains a key weakness: 2025 operating cash flow was -$151.0M and free cash flow was -$159.1M, indicating continued cash burn. While operating cash outflow improved versus 2024 (-$214.9M), free cash flow deteriorated in 2025 (free cash flow growth -24.376), suggesting spending and/or working-capital needs are still heavy as the business scales.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	460.84M	398.99M	266.72M	215.04M	144.31M
Gross Profit	269.47M	251.13M	170.90M	141.02M	92.07M
EBITDA	-205.89M	-242.99M	-365.11M	-384.66M	-689.46M
Net Income	-175.80M	-257.10M	-334.62M	-481.99M	-692.44M
Balance Sheet
Total Assets	1.17B	1.19B	1.04B	1.22B	1.61B
Cash, Cash Equivalents and Short-Term Investments	789.47M	779.67M	806.45M	1.01B	1.41B
Total Debt	237.61M	153.47M	15.15M	20.39M	15.54M
Total Liabilities	456.82M	344.86M	240.18M	174.54M	230.00M
Stockholders Equity	715.41M	840.90M	796.12M	1.05B	1.38B
Cash Flow
Free Cash Flow	-159.13M	-276.39M	-206.67M	-392.63M	-568.18M
Operating Cash Flow	-151.01M	-214.87M	-198.18M	-367.64M	-549.23M
Investing Cash Flow	308.32M	-375.19M	-10.78M	420.02M	249.96M
Financing Cash Flow	72.46M	349.89M	-6.43M	-1.73M	820.20M

Zai Lab Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9688, the sentiment is Negative. The current price of 14.6 is below the 20-day moving average (MA) of 14.82, above the 50-day MA of 14.41, and below the 200-day MA of 21.44, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 49.83 is Neutral, neither overbought nor oversold. The STOCH value of 50.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9688.

Zai Lab Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2696	66 Neutral	HK$23.94B	33.55	25.67%	―	2.57%	18.79%
9966	53 Neutral	HK$8.71B	70.01	13.34%	―	206.58%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9688	47 Neutral	HK$16.36B	-10.93	-30.41%	―	23.87%	30.08%
9995	47 Neutral	HK$65.16B	51.47	-39.64%	―	46.14%	39.56%
2157	40 Underperform	HK$9.52B	61.57	-21.42%	―	240.05%	-140.09%
1877	38 Underperform	HK$33.75B	-22.62	-14.53%	―	38.56%	48.26%

Zai Lab Ltd Corporate Events

Zai Lab Details Board Composition and Committee Roles

Zai Lab Limited has disclosed the current composition of its board of directors and the roles and functions of each member across five key board committees. The announcement details committee chair and member assignments for audit, compensation, nominating and corporate governance, research and development, and commercial oversight, underscoring the company’s emphasis on structured governance and specialized oversight in its corporate management.

The board is led by Chairperson and Chief Executive Officer Dr. Samantha Du, with Dr. John Diekman serving as lead independent director and several other independent directors taking on chair and member roles across the committees. This allocation of responsibilities indicates a robust governance framework intended to support Zai Lab’s strategic, financial, and operational decision-making, providing clarity for investors and other stakeholders on how oversight is organized within the company.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.

Zai Lab Posts Double-Digit 2025 Revenue Growth as Pipeline Advances Toward Global Launches

Zai Lab reported fourth-quarter 2025 revenue of $127.6 million, up 17% year on year, and full-year 2025 revenue of $460.2 million, a 15% increase, while confirming its audited results were prepared under U.S. GAAP and that reconciled Hong Kong-compliant annual results will be published by March 31, 2026. Management highlighted 2025 as a year of disciplined execution, with the oncology candidate zocilurtatug pelitecan advancing toward becoming its first global oncology launch by 2026, a differentiated global pipeline progressing, and key regional programs such as KarXT in China and potential approvals for TIVDAK and TTFields positioning the company for multi-year growth and stronger financial performance.

The company emphasized the rapid pivotal development of zoci across multiple small cell lung cancer and extrapulmonary neuroendocrine carcinoma settings, leveraging its cross-border platform for speed and capital efficiency. It is also expanding the VYVGART franchise, preparing for KarXT’s commercial rollout following its inclusion in a national expert consensus for schizophrenia, and targeting pivotal data readouts in 2026 for povetacicept in IgA nephropathy and elegrobart in thyroid eye disease, moves that could further entrench Zai Lab as an emerging global biopharma leader and enhance its competitive position in specialty therapeutics.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.

Zai Lab Files 2025 Annual Report With U.S. SEC

Zai Lab Limited announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission. The filing, accessible via the SEC’s website and the company’s own site, fulfills key regulatory disclosure obligations for its U.S.-listed securities and provides shareholders and analysts with detailed financial and operational information for the period.

The company also confirmed its current board composition, led by founder Samantha Du as director, chairperson and chief executive officer, alongside a slate of independent directors. This disclosure underscores Zai Lab’s adherence to corporate governance standards across its Hong Kong and U.S. listings, reinforcing transparency and oversight for its global investor base.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.

Zai Lab Outlines Board Composition and Committee Roles

Zai Lab Limited has disclosed the current composition of its board of directors, led by Chairperson and Chief Executive Officer Dr. Samantha Du and supported by a group of independent directors. The announcement details the directors’ specific roles across five board committees, including audit, compensation, nominating and corporate governance, research and development, and commercial, clarifying leadership and oversight responsibilities.

The update highlights which directors chair and sit on each committee, with figures such as Scott W. Morrison leading the audit committee and Michel Vounatsos chairing the commercial committee. This structure underscores Zai Lab’s emphasis on corporate governance, scientific oversight, and commercial strategy, providing investors and other stakeholders with transparency into how board-level responsibilities are allocated.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.

Zai Lab Sets February 26 Board Meeting to Approve and Release 2025 Annual Results

Zai Lab Limited has scheduled a board meeting for February 26, 2026 to consider and approve its audited financial results for the year ended December 31, 2025, prepared under U.S. GAAP and U.S. SEC requirements. If approved, the company will publish the 2025 annual results on the Hong Kong exchange website and its own investor relations site the same day.

Following the release, Zai Lab’s management will host a teleconference and webcast on February 26, 2026 to discuss the results and take questions from the investment community. The company also plans to issue its Hong Kong-compliant annual results announcement by March 31, 2026, including a reconciliation from U.S. GAAP to IFRS, underscoring its commitment to transparency for cross-border shareholders.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.

Zai Lab Limited Announces Equity Incentive Grants

Zai Lab Limited announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan. The company granted options to subscribe for 11,800 ADSs to three employees and restricted share units covering 22,665 ADSs to six employees. This move aligns with the company’s customary practice and aims to incentivize employee performance without attaching performance targets or clawback mechanisms, reflecting a market-competitive approach.

The most recent analyst rating on (HK:9688) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.